Diagnosing the type of lung cancer from a tissue or liquid biopsy is absolutely critical to selecting treatment and determining the patient’s prognosis. However, for many lung cancer patients and their families, the role of tumor tissue in their diagnosis is a mystery. What happens to tissue collected in a biopsy? How is it analyzed? What is involved in getting helpful answers from biomarker testing? The specialized doctors responsible for answering these questions are pathologists. They identify any lung cancer cells in the biopsied tissue, and guide the patient’s biomarker testing. Unfortunately,… Read More
- #LCSM Chat Topic 9/3/2020: Is #Cancer Advocacy for Everyone?
- #LCSM Chat Topic 8/6/2020: Update on #COVID19 and #LungCancer
- #LCSM Chat Topic 6/4/2020: #ASCO20 Roundup for #LungCancer
- #LCSM Chat Topic 5/7/2020: #COVID19 testing and #lungcancer: Where we stand today
- #LCSM Chat Topic 4/2/2020: #COVID19 and #LungCancer
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials COVID-19; antigen test Drugs EGFR epatients immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day